Drug Delivery News and Research

RSS

Drug delivery is a term that refers to the delivery of a pharmaceutical compound into the body. Most common methods of delivery include the preferred non-invasive oral (through the mouth), nasal, pneumonial (inhalation), and rectal routes. Much research is now focussing on nanotechnology as a drug delivery method.

BDSI announces FDA approval of BUNAVAIL sNDA for manufacturing specification change

BioDelivery Sciences International, Inc. announced that the U.S. Food and Drug Administration has approved the company's Supplemental New Drug Application (sNDA) for a manufacturing specification change for BUNAVAIL (buprenorphine and naloxone) buccal film (CIII).

15 Oct 2015

CWRU investigator receives $2.82 million NIH grant to make stealth bombs for brain cancer treatment

A Case Western Reserve University researcher has received a 5-year, $2.82 million National Institutes of Health grant to make, in essence, stealth bombs that slip past the brain's defenses to attack an incurable form of cancer.

15 Oct 2015

Researchers come up with new design for a better liposome

Using computational modeling, researchers at Carnegie Mellon University, the Colorado School of Mines and the University of California, Davis have come up with a design for a better liposome. Their findings, while theoretical, could provide the basis for efficiently constructing new vehicles for nanodrug delivery.

14 Oct 2015

SynAgile announces positive results from Phase 2a trial of continuous intraoral LD/CD therapy

SynAgile Corporation, a privately held pharmaceutical company that develops and commercializes drug delivery systems using its proprietary OraFuse intraoral technology platform, today announced positive results from a proof-of-concept, Phase 2a, open-label clinical trial of continuous intraoral administration of levodopa-carbidopa (LD/CD).

8 Oct 2015

New flame retardant created to replace commercial additives that are often toxic

Inspired by a naturally occurring material found in marine mussels, researchers at The University of Texas at Austin have created a new flame retardant to replace commercial additives that are often toxic and can accumulate over time in the environment and living animals, including humans.

6 Oct 2015

Tris Pharma announces launch of generic TUSSIONEX

Tris Pharma, a specialty pharmaceutical company that develops innovative drug delivery technologies, announced the launch of Tris-labeled generic TUSSIONEX, an extended-release suspension containing hydrocodone polistirex and chlorpheniramine polistirex.

1 Oct 2015

Cornell University, MSKCC jointly open new $10 million Center of Cancer Nanotechnology Excellence

Cornell University, in partnership with Memorial Sloan Kettering Cancer Center, is opening a new $10 million Center of Cancer Nanotechnology Excellence that brings together scientists, engineers, biologists and physicians to develop and translate new cancer care applications based on nanotechnology.

30 Sep 2015

Generex agrees to acquire 51% equity interest in Hema Diagnostic Systems

Generex Biotechnology Corporation today announced that it has entered into a non-binding Letter of Intent (LOI) with Hema Diagnostic Systems, LLC (HDS), a Florida company that designs and manufactures proprietary infectious disease detection technologies.

30 Sep 2015

Researchers develop a technique that uses platelet membranes to coat anticancer drugs

Researchers have for the first time developed a technique that coats anticancer drugs in membranes made from a patient's own platelets, allowing the drugs to last longer in the body and attack both primary cancer tumors and the circulating tumor cells that can cause a cancer to metastasize. The work was tested successfully in an animal model.

30 Sep 2015

FDA accepts Braeburn's resubmission of Probuphine NDA for review

Braeburn Pharmaceuticals, an Apple Tree Partners company, today announced that the U.S. Food and Drug Administration has accepted Braeburn's resubmission of the Probuphine New Drug Application (NDA) for review and set February 27, 2016 as the target date for Agency action.

28 Sep 2015

DNA nanostructures provide novel applications in molecular medicine

Researchers from Aalto University have published an article in the recent Trends in Biotechnology journal. The article discusses how DNA molecules can be assembled into tailored and complex nanostructures, and further, how these structures can find uses in therapeutics and bionanotechnological applications.

25 Sep 2015

BD Life Sciences announces FDA clearance for BD MAX Enteric Parasite Panel

BD Life Sciences, a segment of global medical technology company BD (Becton, Dickinson and Company), today announced the availability of the U.S. Food and Drug Administration cleared BD MAX Enteric Parasite Panel for use on the BD MAX System.

From BD (Becton, Dickinson and Company) 24 Sep 2015

FDA approves Impax Laboratories' generic version of Testred Capsules 10 mg

Impax Laboratories, Inc. today announced that the U.S. Food and Drug Administration has approved its generic version of Testred Capsules 10 mg.

22 Sep 2015

NUS researchers develop new technique to observe nano-bio interactions

Researchers at the National University of Singapore have developed a technique to observe, in real time, how individual blood components interact and modify advanced nanoparticle therapeutics.

16 Sep 2015

US-Ireland partnership awarded £2.9m to develop nanomedicine for treatment of pancreatic cancer

A US-Ireland partnership involving researchers at Queen's University Belfast has been awarded £2.9m to develop new treatments for pancreatic cancer, which is the fifth most common cause of cancer deaths in the UK.

14 Sep 2015

UNC scientists create smarter immune cells to treat Parkinson's disease

As a potential treatment for Parkinson's disease, scientists at the University of North Carolina at Chapel Hill have created smarter immune cells that produce and deliver a healing protein to the brain while also teaching neurons to begin making the protein for themselves.

14 Sep 2015

BioDelivery Sciences and Endo present Phase 2 data on buprenorphine HCl buccal film in patients with chronic pain

Endo Pharmaceuticals Inc., a subsidiary of Endo International plc, and BioDelivery Sciences International, Inc. today presented data from a Phase 2 study for the investigational drug buprenorphine HCl buccal film utilizing BDSI’s patented BioErodible MucoAdhesive (BEMA) drug delivery technology.

11 Sep 2015

Researchers discover new strategy for attacking cancer cells

University of Virginia School of Medicine researchers have discovered a new strategy for attacking cancer cells that could fundamentally alter the way doctors treat and prevent the deadly disease.

11 Sep 2015

UVA researchers identify new strategy for attacking cancer cells

University of Virginia School of Medicine researchers have discovered a new strategy for attacking cancer cells that could fundamentally alter the way doctors treat and prevent the deadly disease. By more selectively targeting cancer cells, this method offers a strategy to reduce the length of and physical toll associated with current treatments.

10 Sep 2015

Impax Laboratories receives FDA notice regarding Hayward manufacturing facility

Impax Laboratories, Inc. today announced that it received written notice from the United States Food and Drug Administration verifying that the Company has successfully addressed all items raised by the FDA in the May 2011 Warning Letter relating to its Hayward, California manufacturing facility.

8 Sep 2015

Drug Delivery News and Research

Further Reading

BDSI announces FDA approval of BUNAVAIL sNDA for manufacturing specification change

CWRU investigator receives $2.82 million NIH grant to make stealth bombs for brain cancer treatment

Researchers come up with new design for a better liposome

SynAgile announces positive results from Phase 2a trial of continuous intraoral LD/CD therapy

New flame retardant created to replace commercial additives that are often toxic

Tris Pharma announces launch of generic TUSSIONEX

Cornell University, MSKCC jointly open new $10 million Center of Cancer Nanotechnology Excellence

Generex agrees to acquire 51% equity interest in Hema Diagnostic Systems

Researchers develop a technique that uses platelet membranes to coat anticancer drugs

FDA accepts Braeburn's resubmission of Probuphine NDA for review

DNA nanostructures provide novel applications in molecular medicine

BD Life Sciences announces FDA clearance for BD MAX Enteric Parasite Panel

FDA approves Impax Laboratories' generic version of Testred Capsules 10 mg

NUS researchers develop new technique to observe nano-bio interactions

US-Ireland partnership awarded £2.9m to develop nanomedicine for treatment of pancreatic cancer

UNC scientists create smarter immune cells to treat Parkinson's disease

BioDelivery Sciences and Endo present Phase 2 data on buprenorphine HCl buccal film in patients with chronic pain

Researchers discover new strategy for attacking cancer cells

UVA researchers identify new strategy for attacking cancer cells

Impax Laboratories receives FDA notice regarding Hayward manufacturing facility

Ultimate guide to the essential tools for the characterization of proteins, polymers and nanoparticles eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo